Literature DB >> 19699182

Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity.

Ling Liu1, Cheng Yang, Christian Herzog, Rohit Seth, Gur P Kaushal.   

Abstract

We demonstrate the effect of proteasome inhibitors in mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-exposed renal tubular epithelial cells (LLC-PK(1) cells) and in a model of cisplatin nephrotoxicity. Immunofluorescence and subcellular fractionation studies revealed cisplatin-induced translocation of AIF from the mitochondria to nucleus. Mcl-1, a pro-survival member of the Bcl-2 family, is rapidly eliminated on exposure of renal cells to cisplatin. Proteasome inhibitors PS-341 and MG-132 blocked cisplatin-induced Mcl-1 depletion and markedly prevented mitochondrial release of AIF. PS-341 and MG132 also blocked cisplatin-induced activation of executioner caspases and apoptosis. These studies suggest that proteasome inhibitors prevent cisplatin-induced caspase-dependent and -independent pathways. Overexpression of Mcl-1 was effective in blocking cisplatin-induced cytochrome c and AIF release from the mitochondria. Downregulation of Mcl-1 by small interfering RNA promoted Bax activation and cytochrome c and AIF release, suggesting that cisplatin-induced Mcl-1 depletion and associated Bax activation are involved in the release of AIF. Expression of AIF protein in the mouse was highest in the kidney compared to the heart, brain, intestine, liver, lung, muscle, and spleen. In an in vivo model of cisplatin nephrotoxicity, proteasome inhibitor MG-132 prevented mitochondrial release of AIF and markedly attenuated acute kidney injury as assessed by renal function and histology. These studies provide evidence for the first time that the proteasome inhibitors prevent cisplatin-induced mitochondrial release of AIF, provide cellular protection, and markedly ameliorate cisplatin-induced acute kidney injury. Thus, AIF is an important therapeutic target in cisplatin nephrotoxicity and cisplatin-induced depletion of Mcl-1 is an important pathway involved in AIF release.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699182     DOI: 10.1016/j.bcp.2009.08.015

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  The role of the ubiquitin-proteasome system in kidney diseases.

Authors:  Hirotaka Fukasawa
Journal:  Clin Exp Nephrol       Date:  2012-06-09       Impact factor: 2.801

2.  Sulforaphane, a natural constituent of broccoli, prevents cell death and inflammation in nephropathy.

Authors:  Carlos Enrique Guerrero-Beltrán; Partha Mukhopadhyay; Béla Horváth; Mohanraj Rajesh; Edilia Tapia; Itzhel García-Torres; José Pedraza-Chaverri; Pál Pacher
Journal:  J Nutr Biochem       Date:  2011-06-17       Impact factor: 6.048

Review 3.  Pathophysiology of acute kidney injury.

Authors:  David P Basile; Melissa D Anderson; Timothy A Sutton
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

4.  Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines.

Authors:  Sham S Kakar; Venkatakrishna R Jala; Miranda Y Fong
Journal:  Biochem Biophys Res Commun       Date:  2012-06-16       Impact factor: 3.575

Review 5.  Pathogenesis of acute kidney injury: foundation for clinical practice.

Authors:  Gilbert R Kinsey; Mark D Okusa
Journal:  Am J Kidney Dis       Date:  2011-05-06       Impact factor: 8.860

6.  Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity.

Authors:  Zsuzsanna K Zsengellér; Lena Ellezian; Dan Brown; Béla Horváth; Partha Mukhopadhyay; Balaraman Kalyanaraman; Samir M Parikh; S Ananth Karumanchi; Isaac E Stillman; Pál Pacher
Journal:  J Histochem Cytochem       Date:  2012-04-17       Impact factor: 2.479

Review 7.  Novel aspects of pharmacological therapies for acute renal failure.

Authors:  Ulrich Kunzendorf; Michael Haase; Lars Rölver; Anja Haase-Fielitz
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

8.  Protective effect of plaunotol against doxorubicin-induced renal cell death.

Authors:  Chatchai Chaotham; Wanchai De-Eknamkul; Pithi Chanvorachote
Journal:  J Nat Med       Date:  2012-07-01       Impact factor: 2.343

9.  Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

Authors:  Nadia Stefanova; Walter A Kaufmann; Christian Humpel; Werner Poewe; Gregor K Wenning
Journal:  Acta Neuropathol       Date:  2012-04-11       Impact factor: 17.088

Review 10.  Preventive and therapeutic effects of MG132 by activating Nrf2-ARE signaling pathway on oxidative stress-induced cardiovascular and renal injury.

Authors:  Wenpeng Cui; Yang Bai; Ping Luo; Lining Miao; Lu Cai
Journal:  Oxid Med Cell Longev       Date:  2013-03-07       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.